Tetranor-PGDM

• Target:

  Prostaglandin Receptor|||Others

• Related Pathways:

  GPCR/G Protein|||Immunology/Inflammation|||Others

• Bioactivity:

  Prostaglandin D2 is synthesized by hematopoietic-type PGD-synthase (H-PGDS) in mast cells and is released in large quantities during allergic and asthmatic anaphylaxis. PGD2 is also produced in the brain by lipocalin-PGD-synthase also known as ?-trace. In the brain, PGD2 produces normal physiological sleep and lowering of body temperature. Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle. tetranor-PGDM is a major metabolite of PGD2 that is detectable in human and mouse urine. The levels of tetranor-PGDM and 2,3-dinor-11?-PGF2? , a related PGD2 metabolite, in human urine were found to be 1.5 ± 0.3 and 0.6 ± ng/mg creatinine, respectively. tetranor-PGDM was detected in murine urine at a level of 8.1 ± 1.3 ng/mg creatinine.

• Smiles:

  O[C@H]1CC(=O)[C@H](CCC(=O)CCCCC(O)=O)[C@H]1CCC(O)=O

• Molecular Formula:

  C16H24O7

• Molecular Weight:

  328.361

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  70803-91-7